What Recent Advances in Gene Editing Actually Mean for Medicine

The gap between gene editing headlines and clinical reality has been a persistent feature of biomedical journalism for decades. Every few years, a new development in molecular biology produces coverage suggesting that genetic diseases are about to become a thing of the past. Understanding what’s actually changed recently—what the CRISPR era has delivered, where the barriers remain, and what realistic expectations look like for the next ten years—requires distinguishing between genuine scientific advances and the recurring pattern of oversold timelines.

The recent period is genuinely exceptional. The approval of the first CRISPR-based therapy for human patients in late 2023 marked a real milestone, not merely a media narrative. But the path from that milestone to broadly accessible genetic medicine is longer and more complex than the headline implies.

What CRISPR Actually Changed

Gene editing—altering specific sequences in DNA—has been technically possible since the 1970s. What changed with CRISPR-Cas9, developed into a practical editing tool around 2012, was the precision and accessibility of the process. Earlier gene editing tools (zinc finger nucleases, TALENs) required custom-engineered proteins for each target site—expensive, slow, and technically demanding. CRISPR uses a guide RNA to direct a protein (Cas9) to a specific DNA sequence, then cuts the DNA at that location. To target a new sequence, you change the guide RNA—a cheap, fast, and relatively simple process.

This democratised gene editing research dramatically. The tool became widely accessible to laboratories that couldn’t afford or develop earlier approaches, which accelerated understanding of gene function, disease mechanisms, and therapeutic possibilities. The decade since CRISPR became practical as a research tool has produced an enormous volume of research that is now feeding into the clinical pipeline.

The limitations of CRISPR-Cas9 include off-target editing (cuts at unintended genomic locations), delivery challenges (getting the editing machinery into the cells that need editing), and a preference for simple “cut and disable” edits over complex “cut and replace” edits. Subsequent development has addressed some of these limitations: base editing and prime editing tools allow specific single-base changes with fewer double-strand breaks and potentially lower off-target effects, significantly expanding the types of edits possible.

The First Approved Therapies: What They Treat and How

Casgevy (exagamglogene autotemcel), approved by the FDA in December 2023 for sickle cell disease and transfusion-dependent beta-thalassemia, is the first CRISPR-based treatment to reach regulatory approval. It works by editing the patient’s own hematopoietic stem cells (the blood-forming cells in bone marrow) outside the body. The edit reactivates fetal hemoglobin production, which compensates for the defective adult hemoglobin that causes both diseases.

The therapeutic results in clinical trials were remarkable: the large majority of patients in trials achieved transfusion independence (beta-thalassemia) or were free from vaso-occlusive crises (sickle cell disease), outcomes that represent a near-curative effect for diseases that previously required lifelong management.

The treatment’s limitations are equally instructive about where gene editing medicine currently is. The process involves harvesting stem cells from the patient, editing them in a specialised laboratory, and re-infusing them after conditioning chemotherapy to clear the bone marrow. The full treatment course takes months, requires specialised medical infrastructure, and involves chemotherapy-associated risks. The cost is approximately $2–3 million per patient, making it one of the most expensive treatments ever approved. It’s currently available at only a handful of specialist centres globally.

These constraints are real and shouldn’t be minimised. At the same time, for patients with severe sickle cell disease or beta-thalassemia, the treatment represents an option that didn’t exist two years ago—one that for a substantial proportion of treated patients means the effective end of a disease that previously imposed severe morbidity and reduced life expectancy.

The Delivery Problem: Still the Biggest Bottleneck

Gene editing works well in cells that can be removed from the body, edited, and reinfused—primarily blood and immune cells. Most of medicine’s most important targets require editing cells that can’t be harvested this way: neurons, cardiomyocytes, hepatocytes in the liver, cells in solid tumours.

Getting editing machinery to these cells in vivo (inside the living body) is the dominant technical challenge in the field. The main current approach is lipid nanoparticles (LNPs)—fat-based particles that encapsulate the editing components and can be injected, primarily concentrating in the liver. LNP delivery to the liver is well-developed; LNP delivery to other organs is an active and difficult research area.

Viral vectors—modified viruses that carry gene editing cargo into cells—remain important for many applications, particularly adeno-associated viruses (AAVs) for some tissue-specific delivery. AAV gene therapies (not editing per se, but gene addition) have been approved for several inherited diseases. AAVs have their own limitations: pre-existing immunity in some patients, limited cargo size, and potential for unintended genomic insertion.

Non-viral delivery systems beyond LNPs are in active development. Extracellular vesicles, engineered virus-like particles, and various nanoparticle formulations are being explored for delivery to tissues that LNPs can’t efficiently reach. This is an area where the science is advancing but where no general solution yet exists.

Inherited Disease: The Near-Term Opportunity

Monogenic diseases—caused by mutations in a single gene—are the most tractable near-term targets for gene editing therapies. The mutation is known, the cellular target is identifiable, and “fixing” or compensating for the mutation is conceptually straightforward even if technically difficult.

The clinical pipeline for single-gene disease is extensive: familial hypercholesterolaemia (high LDL cholesterol from mutations in PCSK9 or LDLR), transthyretin amyloidosis (a progressive nerve and heart disease from misfolded transthyretin protein), alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and several others are in various stages of clinical trials. The liver-delivery advantage of LNPs makes any liver-expressed protein target particularly accessible.

NTLA-2001, developed by Intellia Therapeutics, showed in 2021 that in vivo CRISPR editing—editing directly in living patients using LNPs rather than ex vivo cell modification—was possible and produced durable results in patients with transthyretin amyloidosis. This proof-of-concept for in vivo editing expanded what’s possible with the technology beyond the ex vivo approach used in Casgevy.

Cancer: More Complex Than It Looks

Cancer is a common target in gene editing research and clinical trials, but the challenge is fundamentally different from inherited disease. Cancer is not caused by a single mutation in germline cells—it’s caused by the accumulated somatic mutations in specific cells, with different tumours having different genomic profiles even in the same cancer type. Editing one target rarely addresses the full mutation burden.

The most promising cancer application of gene editing is engineering the patient’s own immune cells to better attack tumours—building on the CAR-T cell therapy approach with gene editing to enhance specificity, reduce exhaustion, and allow off-the-shelf manufacturing rather than patient-specific cell modification. Gene editing makes it possible to make multiple modifications to immune cells simultaneously in ways that previous approaches couldn’t, potentially producing more potent and durable anti-tumour immunity.

These engineered cell therapies are expensive, technically demanding, and work best for blood cancers that interact readily with immune cells. Solid tumours, which represent the majority of cancer deaths, have proven much harder to treat with immune cell approaches due to the immunosuppressive tumour microenvironment.

What to Expect in the Next Decade

A realistic expectation for gene editing medicine in the next decade includes: more approved therapies for monogenic diseases, driven by the infrastructure and regulatory experience established by the first approvals; reduced costs as manufacturing scales and competition increases (though still extraordinarily expensive by conventional drug standards); in vivo editing therapies for liver-expressed targets reaching broad approval; and continued slow progress on delivery to other organs.

What is unlikely in a decade: broadly available gene editing treatments for common complex diseases, which involve many genetic variants each with small effects; cheap and widely accessible single-gene disease treatment in low-income countries; or routine germline editing (editing heritable changes in embryos), which remains both technically immature and subject to international moratoriums following the He Jiankui incident of 2018.

The advances are real and the trajectory is genuinely positive. The honest version of the story is that gene editing medicine is moving from possibility to reality for specific applications, while the journey to broad clinical application is measured in decades rather than years—which is remarkable progress relative to where the field was a decade ago, even if it’s slower than the headlines suggest.